Physician profile
Howard E Bostwick
NPI 1083606818
$1,879.28
in general payments reported to CMS, 2019-2025
13 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $159 · 2021: $33.58 · 2022: $95.25 · 2023: $444 · 2024: $177 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.20 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $413.15 | 2022-2025 | Sucraid |
| Cumberland Pharmaceuticals, INC. | $366.92 | 2019-2025 | Kristalose |
| Abbvie INC. | $239.14 | 2019-2022 | |
| Genzyme Corporation | $159.26 | 2022-2025 | |
| Mirum Pharmaceuticals, INC. | $144.79 | 2025 | Livmarli |
| Janssen Biotech, INC. | $137.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.45 | 2019-2025 | Gattex |
| Travere Therapeutics, INC. | $78.65 | 2019-2023 | Cholbam |
| Ascendis Pharma Endocrinology INC | $62.66 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $53.52 | 2023-2024 | Dupixent |
| Alexion Pharmaceuticals, INC. | $39.70 | 2024 | Strensiq |
| Tandem Diabetes Care, INC. | $33.95 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alnylam Pharmaceuticals INC. | $17.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Bostwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.